REFERENCES Carcinogen metabolism in human lung tissues and the effect of tobacco smoking

REFERENCES
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J
Clin 2008;58:71–96.
2. Mao L, Lee JS, Kurie JM, et al. Clonal genetic alterations in the lungs
of current and former smokers. J Natl Cancer Inst 1997;89:857–862.
3. Bartsch H, Petruzzelli S, De Flora S, et al. Carcinogen metabolism in
human lung tissues and the effect of tobacco smoking: results from
a case—control multicenter study on lung cancer patients. Environ
Health Perspect 1992;98:119–124.
4. Auerbach O, Forman JB, Gere JB, et al. Changes in the bronchial
epithelium in relation to smoking and cancer of the lung; a report of
progress. N Engl J Med 1957;256:97–104.
5. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral
stratified squamous epithelium; clinical implications of multicentric
origin. Cancer 1953;6:963–968.
6. Auerbach O, Hammond EC, Garfinkel L. Changes in bronchial epithelium
in relation to cigarette smoking, 1955–1960 vs. 1970–1977.
N Engl J Med 1979;300:381–385.
7. Boice JD Jr, Fraumeni JF Jr. Second cancer following cancer of the respiratory
system in Connecticut, 1935–1982. Natl Cancer Inst Monogr
1985;68:83–98.
8. de Vries N, Snow GB. Multiple primary tumours in laryngeal cancer.
J Laryngol Otol 1986;100:915–918.
9. Vikram B, Strong EW, Shah JP, et al. Second malignant neoplasms
in patients successfully treated with multimodality treatment for advanced
head and neck cancer. Head Neck Surg 1984;6:734–737.
10. Hung J, Kishimoto Y, Sugio K, et al. Allele-specific chromosome 3p
deletions occur at an early stage in the pathogenesis of lung carcinoma.
JAMA 1995;273:1908.
11. Mao L. Tumor suppressor genes: does FHIT fit? J Natl Cancer Inst 1998;
90:412–414.
12. Wistuba, II, Lam S, Behrens C, et al. Molecular damage in the bronchial
epithelium of current and former smokers. J Natl Cancer Inst
1997;89:1366–1373.
13. Kishimoto Y, Sugio K, Hung JY, et al. Allele-specific loss in chromosome
9p loci in preneoplastic lesions accompanying non-small-cell
lung cancers. J Natl Cancer Inst 1995;87:1224–1229.
14. Kishimoto Y, Murakami Y, Shiraishi M, et al. Aberrations of the p53
tumor suppressor gene in human non-small cell carcinomas of the
lung. Cancer Res 1992;52:4799–4804.
15. Westra WH, Slebos RJ, Offerhaus GJ, et al. K-ras oncogene activation
in lung adenocarcinomas from former smokers. Evidence that K-ras
mutations are an early and irreversible event in the development of
adenocarcinoma of the lung. Cancer 1993;72:432–438.
16. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth
factor receptor in non-small-cell lung carcinomas: correlation between
gene copy number and protein expression and impact on prognosis.
J Clin Oncol 2003;21:3798–3807.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-smallcell
lung cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
18. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science
2004;304:1497–1500.
19. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, et al. The putative tumor
suppressor RASSF1A homodimerizes and heterodimerizes with the
Ras-GTP binding protein Nore1. Oncogene 2002;21:1381–1390.
20. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated
inactivation of RASSF1A from region 3p21.3 in lung, breast and
ovarian tumours. Oncogene 2001;20:1509–1518.
21. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al. Epigenetic inactivation
of RASSF1A in lung and breast cancers and malignant phenotype
suppression. J Natl Cancer Inst 2001;93:691–699.
22. Leid M, Kastner P, Chambon P. Multiplicity generates diversity in
the retinoic acid signalling pathways. Trends Biochem Sci 1992;17:
427–433.
23. Xu XC, Sozzi G, Lee JS, et al. Suppression of retinoic acid receptor
beta in non-small-cell lung cancer in vivo: implications for lung cancer
development. J Natl Cancer Inst 1997;89:624–629.
24. Bérard J, Laboune F, Mukuna M, et al. Lung tumors in mice expressing
an antisense RARbeta2 transgene. FASEB J 1996;10:1091–1097.
25. Toulouse A, Morin J, Dion PA, et al. RARbeta2 specificity in mediating
RA inhibition of growth of lung cancer-derived cells. Lung Cancer
2000;28:127–137.
26. Khuri FR, Lotan R, Kemp BL, et al. Retinoic acid receptor-beta as a
prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol
2000;18:2798–2804.
27. Kim JS, Lee H, Kim H, et al. Promoter methylation of retinoic acid
receptor beta 2 and the development of second primary lung cancers in
non-small-cell lung cancer. J Clin Oncol 2004;22:3443–3450.
28. Khuri FR, Lotan R. Retinoids in lung cancer: friend, foe, or fellow
traveler? J Clin Oncol 2004;22:3435–3437.
29. Peto R, Lopez AD, Boreham J, et al. Mortality from tobacco in developed
countries: indirect estimation from national vital statistics. Lancet
1992;339:1268–1278.
30. Xu H, Spitz MR, Amos CI, et al. Complex segregation analysis reveals
a multigene model for lung cancer. Hum Genet 2005;116:121–127.
31. Denissenko MF, Pao A, Tang M, et al. Preferential formation of
benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.
Science 1996;274:430–432.
32. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced
DNA adducts and lung cancer risk: a molecular epidemiologic
study. J Natl Cancer Inst 2000;92:1764–1772.
33. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer
Inst 1999;91:1194–1210.
34. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision
repair capacity by XPD polymorphisms in lung cancer patients. Cancer
Res 2001;61:1354–1357.
35. Spitz MR, Duphorne CM, Detry MA, et al. Dietary intake of isothiocyanates:
evidence of a joint effect with glutathione S-transferase
polymorphisms in lung cancer risk. Cancer Epidemiol Biomarkers Prev
2000;9:1017–1020.
36. Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention:
a review of the epidemiological evidence. Nutr Cancer 1992;18:1–29.
37. Fortes C, Forastiere F, Farchi S, et al. The protective effect of the
Mediterranean diet on lung cancer. Nutr Cancer 2003;46(1):30–37.
38. Clark LC, Combs GF Jr, Turnbull BW, et al. Effects of selenium supplementation
for cancer prevention in patients with carcinoma of the
skin. A randomized controlled trial. Nutritional Prevention of Cancer
Study Group. JAMA 1996;276:1957–1963.
39. The effect of vitamin E and beta carotene on the incidence of lung
cancer and other cancers in male smokers. The Alpha-Tocopherol,
Beta Carotene Cancer Prevention Study Group. N Engl J Med
1994;330:1029–1035.
40. Omenn GS. Chemoprevention of lung cancers: lessons from CARET,
the beta-carotene and retinol efficacy trial, and prospects for the future.
Eur J Cancer Prev 2007;16(3):184–191.
41. Sporn MB, Dunlop NM, Newton DL, et al. Prevention of chemical
carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed
Proc 1976;35:1332–1338.
42. Tong L, Spitz MR, Fueger JJ, et al. Lung carcinoma in former smokers.
Cancer 1996;78:1004–1010.
43. Strauss G, DeCamp M, Dibiccaro E, et al. Lung cancer diagnosis is
being made with increasing frequency in former cigarette smokers! Proc
Am Soc Clin Oncol 1995;14:362.
44. Virtamo J, Pietinen P, Huttunen JK, et al. Incidence of cancer and
mortality following alpha-tocopherol and beta-carotene supplementation:
a postintervention follow-up. JAMA 2003;290:476–485.
45. Goodman M, Morgan RW, Ray R, et al. Cancer in asbestos-exposed
occupational cohorts: a meta-analysis. Cancer Causes Control 1999;10:
453–465.
46. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination
of beta carotene and vitamin A on lung cancer and cardiovascular
disease. N Engl J Med 1996;334:1150–1155.
47. Hennekens CH, Buring JE, Manson JE, et al. Lack of effect of longterm
supplementation with beta carotene on the incidence of malignant
neoplasms and cardiovascular disease. N Engl J Med 1996;334:
1145–1149.
48. Cullen MR, Barnett MJ, Balmes JR, et al. Predictors of lung cancer
among asbestos-exposed men in the {beta}-carotene and retinol efficacy
trial. Am J Epidemiol 2005;161(3):260–270.
49. Slatore CG, Littman AJ, Au DH. Long-term use of supplemental multivitamins,
vitamin C, vitamin E, and folate does not reduce the risk of
lung cancer. Am J Respir Crit Care Med 2008;177:524–530.
50. Lee JS, Lippman SM, Benner SE, et al. Randomized placebo- controlled
trial of isotretinoin in chemoprevention of bronchial squamous metaplasia.
J Clin Oncol 1994;12:937–945.
51. Kurie JM, Lotan R, Lee JJ, et al. Treatment of former smokers with
9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression
in the bronchial epithelium: results from a randomized placebocontrolled
trial. J Natl Cancer Inst 2003;95:206–214.
52. Soria JC, Moon C, Wang L, et al. Effects of N-(4-hydroxyphenyl)retinamide
on hTERT expression in the bronchial epithelium of cigarette smokers.
J Natl Cancer Inst 2001;93:1257–1263.
53. Decker J, Goldstein JC. Risk factors in head and neck cancer. N Engl J
Med 1982;306:1151–1155.
54. Wynder EL, Stellman SD. Impact of long-term filter cigarette usage
on lung and larynx cancer risk: a case-control study. J Natl Cancer Inst
1979;62:471–477.
55. Gluckman JL, Crissman JD. Survival rates in 548 patients with multiple
neoplasms of the upper aerodigestive tract. Laryngoscope 1983;93:71–74.
56. Yellin A, Hill LR, Benfield JR. Bronchogenic carcinoma associated with
upper aerodigestive cancers. J Thorac Cardiovasc Surg 1986;91:674–683.
57. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer.
N Engl J Med 1993;328:184–194.
58. Vikram B. Changing patterns of failure in advanced head and neck
cancer. Arch Otolaryngol 1984;110:564–565.
59. Warren S, Gates O. Multiple primary malignant tumors: a survey of
the literature and statistical study. Am J Cancer 1932;16:1358–1403.
60. Califano J, Westra WH, Koch W, et al. Unknown primary head and
neck squamous cell carcinoma: molecular identification of the site of
origin. J Natl Cancer Inst 1999;91:599–604.
61. Califano J, Leong PL, Koch WM, et al. Second esophageal tumors in
patients with head and neck squamous cell carcinoma: an assessment of
clonal relationships. Clin Cancer Res 1999;5:1862–1867.
62. Scholes AG, Woolgar JA, Boyle MA, et al. Synchronous oral carcinomas:
independent or common clonal origin? Cancer Res 1998;58:
2003–2006.
63. Lippman SM, Hong WK. Not yet standard: retinoids versus second
primary tumors. J Clin Oncol 1993;11:1204–1207.
64. Lippman SM, Hong WK. Second malignant tumors in head and neck
squamous cell carcinoma: the overshadowing threat for patients with
early-stage disease. Int J Radiat Oncol Biol Phys 1989;17:691–694.
65. Larson JT, Adams GL, Fattah HA. Survival statistics for multiple primaries
in head and neck cancer. Otolaryngol Head Neck Surg 1990;
103:14–24.
66. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary
tumors with isotretinoin in squamous-cell carcinoma of the head and
neck. N Engl J Med 1990;323:795–801.
67. Benner SE, Pajak TF, Lippman SM, et al. Prevention of second primary
tumors with isotretinoin in patients with squamous cell carcinoma
of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;
86:140–141.
68. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of lowdose
isotretinoin for prevention of second primary tumors in stage I and
II head and neck cancer patients. J Natl Cancer Inst 2006;98:441–450.
69. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of
stage I lung cancer with high-dose vitamin A. J Clin Oncol 1993;11:
1216–1222.
70. Bolla M, Lefur R, Ton Van J, et al. Prevention of second primary tumours
with etretinate in squamous cell carcinoma of the oral cavity and
oropharynx. Results of a multicentric double-blind randomised study.
Eur J Cancer 1994;30A:727–729.
71. van Zandwijk N, Dalesio O, Pastorino U, et al. EUROSCAN, a randomized
trial of vitamin A and N-acetylcysteine in patients with head
and neck cancer or lung cancer. For the European Organization for
Research and Treatment of Cancer Head and Neck and Lung Cancer
Cooperative Groups. J Natl Cancer Inst 2000;92:977–986.
72. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup
trial of isotretinoin to prevent second primary tumors in stage I
non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605–618.
73. Mayne ST, Cartmel B, Baum M, et al. Randomized trial of supplemental
beta-carotene to prevent second head and neck cancer. Cancer Res
2001;61:1457–1463.
74. Schabath MB, Hernandez LM, Wu X, et al. Dietary phytoestrogens
and lung cancer risk. JAMA 2005;294:1493–1504.
75. Kurie JM, Shin HJ, Lee JS, et al. Increased epidermal growth factor
receptor expression in metaplastic bronchial epithelium. Clin Cancer
Res 1996;2:1787–1793.
76. Rusch V, Baselga J, Cordon-Cardo C, et al. Differential expression of the
epidermal growth factor receptor and its ligands in primary non-small cell
lung cancers and adjacent benign lung. Cancer Res 1993;53:2379–2385.
77. Tang X, Shigematsu H, Bekele BN, et al. EGFR tyrosine kinase domain
mutations are detected in histologically normal respiratory epithelium
in lung cancer patients. Cancer Res 2005;65:7568–7572.
78. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously
treated non-small-cell lung cancer. N Engl J Med 2005;353:123–132.
79. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive
care in previously treated patients with refractory advanced nonsmall-
cell lung cancer: results from a randomised, placebo-controlled,
multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet
2005;366:1527–1537.
80. Mao JT, Fishbein MC, Adams B, et al. Celecoxib decreases Ki-67 proliferative
index in active smokers. Clin Cancer Res 2006;12:314–320.
81. Kim ES, Hong WK, Lee JJ, et al. A randomized double-blind study of
the biological effects of celecoxib as a chemopreventive agent in current
and former smokers. J Clin Oncol 2008;26S:1501.
82. Keith RL, Geraci MW. Prostacyclin in lung cancer. J Thorac Oncol
2006;1(6):503–505.
83. Govindarajan R, Ratnasinghe L, Simmons DL, et al. Thiazolidinediones
and the risk of lung, prostate, and colon cancer in patients with diabetes.
J Clin Oncol 2007;25:1476–1481.
84. Nemenoff RA, Weiser-Evans M, Winn RA. Activation and molecular
targets of peroxisome proliferator-activated receptor-gamma ligands in
lung cancer. PPAR Res 2008;2008:156875.
85. Nemenoff RA. Peroxisome proliferator-activated receptor-gamma in
lung cancer: defining specific versus “off-target” effectors. J Thorac
Oncol 2007;2(11):989–992.
86. Lam S, leRiche JC, McWilliams A, et al. A randomized phase IIb trial
of pulmicort turbuhaler (budesonide) in people with dysplasia of the
bronchial epithelium. Clin Cancer Res 2004;10(19):6502–6511.
87. van den Berg RM, van Tinteren H, van Zandwijk N, et al. The influence
of fluticasone inhalation on markers of carcinogenesis in bronchial
epithelium. Am J Respir Crit Care Med 2007;175(10):1061–1065.
88. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl)retinamide
in the chemoprevention of squamous metaplasia and dysplasia of the
bronchial epithelium. Clin Cancer Res 2000;6:2973–2979.
89. Arnold AM, Browman GP, Levine MN, et al. The effect of the synthetic
retinoid etretinate on sputum cytology: results from a randomised trial.
Br J Cancer 1992;65:737–743.
90. McLarty JW, Holiday DB, Girard WM, et al. Beta-carotene, vitamin
A, and lung cancer chemoprevention: results of an intermediate endpoint
study. Am J Clin Nutr 1995;62:1431S–1438S.
91. Heimburger DC, Alexander CB, Birch R, et al. Improvement in bronchial
squamous metaplasia in smokers treated with folate and vitamin
B12. Report of a preliminary randomized, double-blind intervention
trial. JAMA 1988;259:1525–1530.